Stablepharma sign exclusive supply agreement to produce the world’s first fridge-free Tetanus diphtheria vaccine

Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) European vaccine manufacturer, are delighted to announce that we have signed a definitive agreement for the exclusive bulk supply and commercialisation of the Tetanus diphtheria vaccine, on September 20th, 2022. This agreement follows the head of terms signed in 2022 and consolidates the relationship […]

Read More

New Data demonstrates StablevaX™-Td Vaccine Stable after 12 months at +45°C

Stablepharma and BB-NCIPD Ltd (Bul Bio) establish thermostability of StablevaX™-Td Vaccine After Exposure to +45°C for 12 months In-vitro and In-vivo Studies Pave the Way for Fridge-Free Vaccines Stablepharma Ltd and BB-NCIPD Ltd (Bul Bio) formed a strategic partnership in 2021 to produce the world’s first fridge-free Tetanus diphtheria (Td) vaccine, StablevaX™-Td. Encouraging potency and […]

Read More

Stablepharma and a World Leader in Sterile Manufacturing Announce Partnership to Manufacture the first Fridge-Free Tetanus diphtheria (Td) Vaccine

June 15th, 2022 London, UK – Stablepharma Ltd., a UK-based biotechnology company pioneering fridge-free vaccines today announced a collaboration agreement with a world leader in sterile manufacturing and serving science, to manufacture thermostable Tetanus diphtheria (Td) vaccines at their facilities in Italy. “Our new partner is one of the world’s leading sterile manufacturing companies, offering a […]

Read More

A new generation of COVID-19 vaccines – the latest developments from preclinical and clinical trials?

In the UK Government strategy ‘Living with COVID’, COVID-19 vaccines represent the first line of defence against SARS-CoV-2. Advances in vaccine technologies allowed manufacturers to develop the first generation of COVID-19 vaccines in record time (see Research from the House of Commons Library and POST on COVID-19 vaccines). Current vaccines are highly effective against hospitalisation […]

Read More

Stablepharma Ltd has achieved a scientific breakthrough, demonstrating that a fridge-free Tetanus diphtheria (Td) vaccine is possible

Stablepharma has achieved an important milestone with the Td-StablevaX-M™, having successfully demonstrated stability of the reformulated Td vaccine for up to 10 months at +45ºC in collaboration with our strategic partner BB–NCIPD Ltd (Bul Bio). Td-StablevaX-M™ is a pre-filled disposable syringe containing dry stabilised tetanus diptheria vaccine for administration by injection following rehydration. Results demonstrate […]

Read More

Stablepharma Ltd welcomes another new member to the UK Team

Anh Go joins the company as Strategy and Operations Manager and brings a wealth of diverse and cross-sector experience from healthcare, life science and government. Prior to joining Stablepharma, Anh was part of the Healthcare and Life Sciences Consulting Practice at KPMG in the UK and Australia, where she focused on managing global patient pathway […]

Read More

Daniela Maria Briceño Garcia joins the Stablepharma Science Team

Stablepharma is delighted to announce another new recruit to the Science team in Madrid, Spain based at Stablepharma’s Centre of Excellence (CoE) in Qube Technology Park.  With a Bachelors degree in Chemistry from the Universidad de Los Andes – Venezuela and a Biochemistry Master’s Degree from Harvard University, Daniela Briceño Garcia has more than 15 […]

Read More